Search review questions

Anxiety (STAI‐state) subgroup 1: children vs. adults ‐ adults · people with cancer

Anxiety (STAI‐state) subgroup 2: short‐term vs. medium‐term ‐ short‐term (≤ 4 weeks) · people with cancer

Anxiety (STAI‐state) subgroup 2: short‐term vs. medium‐term ‐ medium‐term (> 4 weeks to < 8 weeks) · people with cancer

Bodily pain (SF‐8) ‐ medium‐term (> 4 weeks to < 8 weeks) · people with cancer

Bodily pain (SF‐8) ‐ long‐term (≥ 8 weeks) · people with cancer

Anxiety (STAI‐state) · people with cancer

'Substantial benefit' (≥ 50% reduction in pain or PGIC very much improved) · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

'Moderate benefit' (≥ 30% reduction in pain or PGIC much or very much improved) · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

Withdrawals due to adverse events · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

Withdrawals due to lack of efficacy · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

Serious adverse events · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

Death · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)

Breathlessness: change from baseline1 · adults with refractory breathlessness

Breathlessness: post‐treatment score1 · adults with refractory breathlessness

Breathlessness: post‐treatment score1 · adults with refractory breathlessness

Exercise tolerance: 6MWT5 ‐ total distance · adults with refractory breathlessness

Exercise tolerance: 6MWT5‐ change from baseline · adults with refractory breathlessness

Adverse events: constipation · adults with refractory breathlessness

Adverse events: nausea and vomiting · adults with refractory breathlessness

Adverse events: drowsiness · adults with refractory breathlessness

Quality of life7 · adults with refractory breathlessness

Breathlessness: post‐treatment score1 · adults with refractory breathlessness

Cry duration Seconds cry time during procedure or proportion of crying during procedure. Crying was measured during and up to 3 minutes following completion of vaccination. · Infants 1 to 12 months during vaccination

All pain scores during injection Due to range of pain scores used, data analysed using SMDs. Pain scores were measured during and up to 3 minutes following completion of vaccination. · Infants 1 to 12 months during vaccination

NIPS score during injection The NIPS was measured during and up to 3 minutes following completion of vaccination. · Infants 1 to 12 months during vaccination

Heart rate after injection Heart rate in the period following completion of the injections was measured in 2 studies. · Infants 1 to 12 months during vaccination

Adverse events · Infants 1 to 12 months during vaccination

At least 50% of maximum pain relief over 4 to 6 h · adults with acute postoperative pain

Participants remedicating within 4 to 6 h · adults with acute postoperative pain

Participants with at least one adverse event · adults with acute postoperative pain

Participants with a serious adverse event · adults with acute postoperative pain

Cumulative pain score from the end of operation (0 hours) to 72 hours · adults aged ≥ 18 years undergoing elective surgery at any surgical site

Serious adverse events · adults aged ≥ 18 years undergoing elective surgery at any surgical site

Mean pain score at 12, 24, 48, 72, and 96 hours following surgery · adults aged ≥ 18 years undergoing elective surgery at any surgical site

Time to first postoperative opioid dose · adults aged ≥ 18 years undergoing elective surgery at any surgical site

Total postoperative opioid consumption over first 72 hours · adults aged ≥ 18 years undergoing elective surgery at any surgical site

Percentage of participants not requiring postoperative opioids over initial 72 hours · adults aged ≥ 18 years undergoing elective surgery at any surgical site

Health economic assessment · adults aged ≥ 18 years undergoing elective surgery at any surgical site

Incidence of adverse events within 30 days of surgery · adults aged ≥ 18 years undergoing elective surgery at any surgical site

Patient‐reported outcomes · adults aged ≥ 18 years undergoing elective surgery at any surgical site

Substantial benefit: ≥ 50% reduction in pain PGIC much improved · adults with chronic neuropathic pain

Moderate benefit: ≥ 30% reduction in pain PGIC much or very much improved · adults with chronic neuropathic pain

Lack of efficacy withdrawal in randomised double‐blind phase · adults with chronic neuropathic pain

Adverse event withdrawal in randomised double‐blind phase · adults with chronic neuropathic pain

Serious adverse events · adults with chronic neuropathic pain

Deaths · adults with chronic neuropathic pain

Moderate benefit: at least 30% reduction in pain, or PGIC much or very much improved · Adults with chronic neuropathic pain

Substantial benefit: at least 50% reduction in pain, or PGIC much improved · Adults with chronic neuropathic pain

Lack of efficacy withdrawal in randomised double‐blind phase · Adults with chronic neuropathic pain

Adverse event withdrawal in randomised double‐blind phase · Adults with chronic neuropathic pain